uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene...
377 insider sale filings on record · latest filing 2026-07-07.
No open-market insider purchases (SEC Form 4 code P) on record for QURE.